ArticleAntimicrobial agents and chemotherapy2004
Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis.
Article in Antimicrobial agents and chemotherapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 61 citations in OpenAlex.
- Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research.Angewandte Chemie (International ed. in English) · 2025Review
- Animal models in tuberculosis metabolomics: a systematic review of current evidence and the road to translational relevance.Frontiers in molecular biosciences · 2025Review
- A modified BPaL regimen for tuberculosis treatment replaces linezolid with inhaled spectinamides.eLife · 2024Article
- Galleria mellonella-intracellular bacteria pathogen infection models: the ins and outs.FEMS microbiology reviews · 2023Review
- Article
- Pharmacokinetics and Target Attainment of SQ109 in Plasma and Human-Like Tuberculosis Lesions in Rabbits.Antimicrobial agents and chemotherapy · 2021Article
- Efficacy of BCG Vaccination Depends on Host Genetics.Bulletin of experimental biology and medicine · 2021Article
- Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010-2020 Review.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Drug Resistance of Mouse Somatic Cells to Rifampicin in Experimental Tuberculosis.Bulletin of experimental biology and medicine · 2021Article
- One Size Fits All? Not inFrontiers in cellular and infection microbiology · 2021Review
- Article
- Structural Modifications of 3-Triazeneindoles and Their Increased Activity AgainstAntibiotics (Basel, Switzerland) · 2020Article
- Article
- Anti-Mycobacterium activity of microbial peptides in a silkworm infection model with Mycobacterium smegmatis.The Journal of antibiotics · 2017Article
- In Vitro Activity of 3-Triazeneindoles against Mycobacterium tuberculosis and Mycobacterium avium.Antimicrobial agents and chemotherapy · 2016Article
- Potent antimycobacterial activity of the pyridoxal isonicotinoyl hydrazone analog 2-pyridylcarboxaldehyde isonicotinoyl hydrazone: a lipophilic transport vehicle for isonicotinic acid hydrazide.Molecular pharmacology · 2014Article
- Influence of vehicles used for oral dosing of test molecules on the progression of Mycobacterium tuberculosis infection in mice.Antimicrobial agents and chemotherapy · 2012Article
- Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.Future microbiology · 2012Review
- How "humane" is your endpoint? Refining the science-driven approach for termination of animal studies of chronic infection.PLoS pathogens · 2012Article
- Identification of SQ609 as a lead compound from a library of dipiperidines.Bioorganic & medicinal chemistry letters · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
Abstract
We evaluated the use of a simple and easy-to-obtain potential marker of tuberculosis (TB) drug efficacy, body weight, and correlated weight loss or gain with the number of CFU of Mycobacterium tuberculosis in lungs and spleens of infected mice. C3H mice were infected intravenously with 10(6) CFU of virulent M. tuberculosis H37Rv, and body weight was evaluated for several weeks after infection. At day 20, infected untreated mice consistently lost more than 25% of their body weight. Chemotherapy with selected orally active anti-TB drugs was initiated 7 days following infection and continued for 13 days. Drugs that were administered daily by gavage included isoniazid (INH), ethambutol (EMB), rifampin (RIF), and moxifloxacin (MXF). At the most effective doses, each of these drugs inhibited bacterial growth and abolished infection-induced body weight loss. Chemotherapy with 1/10 the standard dose of INH determined in accepted long-term murine models of TB also prevented body weight loss, while chemotherapy with 1/10 the standard dose of RIF did not. With only 2 weeks of chemotherapy, we observed a good reverse correlation between CFU in lung or spleen and body weight of mice. The simple measurement of weight in TB-infected drug-treated mice required only a weight balance, and go/no-go drug efficacy data was available on day 20 without the necessity of prolonged drug treatment and long (3 weeks or more) in vitro culture times to obtain organ CFU values.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.